0JDK.LSE Iovance Biotherapeutics Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -34.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0JDK.LSE undervalued?
Graham numberThe Graham number of Iovance Biotherapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Iovance Biotherapeutics Inc. fundamental analysis
No fundamental analysis for Iovance Biotherapeutics Inc. yet.
Iovance Biotherapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Iovance Biotherapeutics Inc.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; …
Full company profileIovance Biotherapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Iovance Biotherapeutics Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | - | - | - | 1.19M | 164M | 264M | 341M |
| Gross Profit | -978K | -952K | -956K | -8.12M | -8.71M | -14.0M | -21.1M | -9.57M | 17.7M | 54.4M | 133M |
| Operating Income | -53.6M | -92.9M | -128M | -207M | -262M | -343M | -399M | -461M | -395M | -398M | -266M |
| EBITDA | -43.2M | -91.9M | -127M | -189M | -251M | -328M | -375M | -427M | -331M | -351M | -226M |
| Net Income | -52.9M | -92.1M | -124M | -198M | -260M | -342M | -396M | -444M | -372M | -391M | -253M |
| EPS | -0.96 | -1.41 | -1.27 | -1.59 | -1.88 | -2.23 | -2.49 | -1.89 | -1.28 | -1.09 | -0.56 |
| Balance Sheet | |||||||||||
| Total Assets | 172M | 155M | 481M | 345M | 768M | 777M | 664M | 780M | 910M | 913M | 916M |
| Total Liabilities | 4.97M | 9.89M | 14.6M | 45.7M | 112M | 156M | 164M | 196M | 200M | 215M | 179M |
| Shareholders' Equity | 167M | 145M | 466M | 299M | 656M | 622M | 500M | 585M | 710M | 699M | 736M |
| Cash & Short-term Investments | 166M | 145M | 469M | 307M | 629M | 504M | 472M | 280M | 324M | 297M | 298M |
| Total Debt | - | - | - | 11.5M | 51.7M | 71.5M | 85.4M | 75.9M | 58.3M | 93.8M | 46.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -32.7M | -78.7M | -101M | -159M | -205M | -228M | -293M | -362M | -353M | -302M | -266M |
| Capital Expenditure | 1.52M | 1.03M | 1.20M | 6.92M | 46.8M | 37.6M | 20.4M | 22.3M | 11.1M | 33.8M | 24.1M |
| Free Cash Flow | -34.2M | -79.7M | -102M | -166M | -252M | -266M | -313M | -384M | -364M | -336M | -290M |
| Ratios | |||||||||||
| ROE | -31.7% | -63.3% | -26.5% | -66.1% | -39.5% | -55.1% | -79.2% | -76.0% | -52.4% | -56.0% | -34.3% |
| ROA | -30.8% | -59.3% | -25.7% | -57.3% | -33.8% | -44.0% | -59.6% | -56.9% | -40.9% | -42.8% | -27.6% |
| Net Profit Margin | - | - | - | - | - | - | - | -37,345.4% | -226.8% | -148.4% | -74.0% |
| Debt to Equity | - | - | - | 0.04x | 0.08x | 0.12x | 0.17x | 0.13x | 0.08x | 0.13x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Iovance Biotherapeutics Inc. dividends
Iovance Biotherapeutics Inc. has not paid dividends in the last 9 fiscal years.
Who owns Iovance Biotherapeutics Inc.
- Insiders 0.35%
- Institutions 70.76%
- Public & others 28.88%
- Free float 394M
Iovance Biotherapeutics Inc. company profile
- Company name
- Iovance Biotherapeutics Inc.
- Ticker
- 0JDK.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 975
- Fiscal year end
- December
- Address
- 300 Rouse Blvd., Philadelphia, PA, United States, 19112
- Phone
- (650) 260-7120
- Website
- iovance.com
About Iovance Biotherapeutics Inc.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in Philadelphia, Pennsylvania.
Iovance Biotherapeutics Inc. management
10- Dr. Frederick G. Vogt Esq., J.D., Ph.D.Interim CEO, President, General Counsel, Corporate Secretary & Director · born 1974
- Ms. Corleen M. RocheChief Financial Officer · born 1966
- Dr. Igor P. Bilinsky Ph.D.Chief Operating Officer · born 1973
- Dr. Raj K. Puri M.D., Ph.D.Chief Regulatory Officer · born 1956
- Mr. Daniel G. KirbyChief Commercial Officer · born 1972
- Ms. Sara PellegrinoSenior Vice President of Investor Relations & Corporate Communications
- Ms. Tracy WintonExecutive Vice President of Human Resources
- Mr. Howard B. Johnson M.B.A.Chief Business Officer · born 1960
- Mr. Kevin SmythExecutive Vice President of Quality
- Dr. Brian Gastman M.D.Executive Vice President of Translational Medicine & Research